Overview

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Status:
Completed

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

This randomized, placebo-controlled, Phase II trial will compare the combination of erlotinib with pazopanib (providing concurrent EGFR and VEGFR inhibition) with erlotinib alone in the second- or third-line treatment of patients with advanced NSCLC. This study will be conducted though the Sarah Cannon Research Consortium, a community-based clinical trial network.

Phase:

Phase 2

Details

Lead Sponsor:

SCRI Development Innovations, LLC

Collaborators:

GlaxoSmithKline
OSI Pharmaceuticals

Treatments:

Erlotinib Hydrochloride